Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Prurigo Nodularis Treatment Market

Prurigo Nodularis Treatment Market Size

Report ID: GMI3849
Published Date: Dec 2022
Report Format: PDF

Download Free Sample

Prurigo Nodularis Treatment Market Size

Prurigo Nodularis Treatment Market size crossed USD 2 billion in 2022 and is slated to depict a 4% CAGR from 2023 to 2032.

The consistent expansion of the pharmaceutical and biotechnology industry globally is among the leading factors spurring the demand for prurigo nodularis treatment. The consistently expanding geriatric population base and the subsequent rise in the burden of chronic diseases have encouraged pharmaceutical manufacturers worldwide to make significant R&D investments and develop novel antibiotics, treatments, and vaccines.

Prurigo Nodularis Treatment Market

To get key market trends

Download Free Sample

Besides, the ongoing advancements focused on fulfilling the healthcare requirements of people living in emerging economies are likely to offer an anticipated boost to the pharmaceutical sector.

Prurigo Nodularis Treatment Market Report Attributes
Report Attribute	Details
Base Year:	2022
Prurigo Nodularis Treatment Market Size in 2022:	2 Billion (USD)
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	4%
2032 Value Projection:	2.5 Billion (USD)
Historical Data for:	2018 to 2022
No. of Pages:	105
Tables, Charts & Figures:	126
Segments covered:	Product, Distribution Channel, and Region
Growth Drivers:	Growing pharmaceutical and biotechnology industry Rising focus on orphan drug development Increasing prevalence of prurigo nodularis treatment industry in developing nations
Pitfalls & Challenges:	Limited approved targeted therapy/drug in the market

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for prurigo nodularis treatment garnered over USD 2 billion in 2022 and is poised to witness a 4% CAGR from 2023 to 2032 owing to the flourishing biotechnology and pharmaceutical sectors globally.

Corticosteroids segment is anticipated to accumulate more than 35.5% market share by 2032 due to the proven efficacy of corticosteroids in relieving the symptoms of prurigo nodularis.

Prurigo nodularis treatment market from the retail pharmacies segment amassed over USD 800 million in 2022 attributed to the increasing disease prevalence and wide range availability of a variety of medications at competitive prices.

Teva Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi, GlaxoSmithKline plc., Merck & Co. Inc., Bayer AG, Johnson & Johnson Services Inc., Galderma, and Takeda Pharmaceuticals are the prominent companies operating in the market.